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ORIGINAL INVESTIGATION
Increased FGF23 serum level is 
associated with unstable carotid plaque in type 
2 diabetic subjects with internal carotid stenosis
Federico Biscetti1,2, Giuseppe Straface4, Carlo Filippo Porreca2,3, Giovanni Bertoletti5, Claudio Vincenzoni6, 
Francesco Snider6, Egidio Stigliano7, Vincenzo Arena7, Flavia Angelini2, Giovanni Pecorini2,3, Antonio Bianchi8, 
Raffaele Landolfi3 and Andrea Flex2,3*
Abstract 
Background: The object of this study was to investigate the potential role of FGF23 on plaque stability in type 2 
diabetic patients with internal carotid artery stenosis.
Methods: In this retrospective observational study, we analyzed FGF23 serum level in 361 type 2 diabetic patients 
with internal carotid artery stenosis undergoing carotid endarterectomy and in 598 diabetic controls without carotid 
atherosclerosis.
Results: We found that FGF23 median serum levels was significantly higher in patients than in diabetic controls [67.7 
(59.5–77.8) pg/mL and 43.89 (37.5–50.4), P < 0.001] and was significantly and independently associated with unstable 
plaque in patients with internal carotid artery stenosis [OR, 5,71 (95 % CI, 2.09–15.29].
Conclusions: We have found, for the first time, that FGF23 could be associated with unstable plaque in type 2 dia-
betic patients with internal carotid artery stenosis.
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Background
Cerebrovascular diseases are a major cause of death and 
several studies found that unstable plaques increased 
the risk of ischemic stroke [1]. An important role in 
the mechanism of mineral metabolism, fundamental 
in plaque stability, is played by glycoprotein fibroblast 
growth factor 23 (FGF23) [2, 3]. FGF23, a hormone 
secreted primarily by osteocytes and to a lesser extent 
by osteoblasts, is involved in the regulation of vitamin D 
metabolism, phosphorus homeostasis and bone miner-
alization. In particular, it inhibits activation of calcitriol 
[1,25(OH)2D], induces urinary phosphorous excretion 
and suppresses parathyroid hormone (PTH) synthesis 
[3–5]. In patients undergoing hemodialysis, increased 
serum FGF23 levels were an independent risk of coro-
nary artery disease (CAD) and mortality in patients 
with chronic kidney disease [6, 7]. Recently, FGF23 has 
been found to be associated with vascular dysfunc-
tion and total body atherosclerosis [8, 9]. Hu et al. have 
shown that serum FGF23 levels exhibit positive and 
independent associations with the presence of CAD and 
the cumulative number of stenotic vessels [10]. On the 
other hand, in another study on patients with normal 
renal function, the authors report that circulating FGF23 
did not correlate with coronary artery calcification [11]. 
Increased FGF23 levels, in patients with cardiovascular 
disease, were a predictor of cardiac events [12] and have 
been associated with left ventricular hypertrophy [9, 13] 
and prevalent cardiovascular disease in elderly individu-
als with normal renal function in the population stud-
ied [14]. Despite the potential involvement of FGF23 in 
vascular calcification, clinical data on the association 
between serum FGF23 and cardiovascular pathology 
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are limited and discordant [6, 15]. It is not completely 
understood how the association between FGF23 concen-
trations and outcome is influenced by the background 
cardiovascular risk and might be different between pop-
ulation-based cohorts compared to those selected for 
elevated cardiovascular risk or previous events. Type 2 
diabetes (T2D) has been associated with higher rates of 
cardiovascular disease, thus showing the evaluation of 
FGF23 and its relationship with cardiovascular disease 
in T2D is of interest. Although the role of FGF23 in the 
development of atherosclerosis is suggested, there has 
been no clinical evidence about FGF23 levels and carotid 
plaque stability. The present study evaluated whether 
serum FGF23 level is associated with internal carotid 
artery stenosis, defined as high-grade (>70  %) carotid 
stenosis (ICAS), and with carotid plaque stability and 
correlates with other inflammatory cytokines [High-Sen-
sitivity C-reactive protein (Hs-CRP) and interleukin-6 
(IL-6)]. We also included osteoprotegerin (OPG) lev-
els in analyzing the possible association of FGF23 with 
unstable plaque.
Methods
Study Population
We studied 361 consecutive T2D patients, with ICAS 
(mean age 72.3  ±  4.2  years) who underwent a carotid 
endarterectomy, recruited among subjects consecutively 
admitted to the Department of Vascular Surgery at the A. 
Gemelli University Hospital of Rome and to the Depart-
ment of Vascular Surgery at the St M. Goretti Hospi-
tal, Latina (Italy) and 598 diabetic subjects (mean age 
71.9 ± 3.9 years) without internal carotid artery stenosis 
(WICAS), recruited among subjects consecutively admit-
ted to the Department of Internal Medicine at the A. 
Gemelli University Hospital of Rome from 1 January 2009 
to 15 February 2015. The diabetic patients WICAS were 
matched according to sex and age and were without Dop-
pler ultrasound evidence of atherosclerosis or clinical or 
radiologic evidence of cerebrovascular disease. A carotid 
endarterectomy was performed according to established 
criteria [16–18]. All subjects were Caucasian, from cen-
tral and southern Italy. All participants had undergone 
a basic vascular evaluation, including a clinical vascular 
examination, a thorough color-coded echo flow imag-
ing of the accessible arterial tree and an ECG at rest. The 
patients underwent an additional neurological evalua-
tion and a cerebral CT to assess symptoms and/or cer-
ebral infarction related to ICAS. For each study patient, 
clinical data and history regarding risk factors such as 
age, hypertension, hypercholesterolemia and smok-
ing were obtained. Height and weight were measured 
and the body mass index (BMI) calculated as weight/
height2 (kg/m2). Diabetes mellitus was determined by 
the presence of an existing diagnosis, fasting blood glu-
cose  >  126  mg/dL, glycohemoglobin A1c  >5.8  % or by 
use of anti-diabetic medication or insulin. Hypertension 
was defined as a systolic blood pressure >130 mmHg and 
a diastolic blood pressure > 85 mmHg or by use of anti-
hypertensive medications. Hypercholesterolemia was 
determined by a serum cholesterol value of >220 mg/dL 
or by use of cholesterol-lowering medications. Patients 
were classified as nonsmokers, if they had never smoked 
or if they had stopped smoking ≥1 year before the study. 
All other patients were classified as smokers. We calcu-
lated the estimated glomerular filtration rate (eGFR) with 
the Chronic Kidney Disease Epidemiology Collabora-
tion equation (eGFR = 175 × standardized S−1.154creatinine × 
age−0.203 × 1.212 [if black] × 0.742 [if female]), in which 
the GFR is expressed as mL/min per 1.73  m2 of body 
surface area and Screatinine is expressed in mg/dL [6]. The 
eGFR was categorized according to established clinical 
cutoff points:  ≥90, 60–89 and 15–59  mL/min per 1.73 
m2. No participants in our sample had an eGFR <60 ml/
min.
The preoperative evaluation included an ultrasound 
assessment of plaque density by color-coded echo flow 
imaging confirmed by angiography. Patients with malig-
nant neoplasms, severe renal (eGFR <60 ml/min) or liver 
disease, serous membrane chamber fluid, severe oedema, 
hypothyroidism and osteoporosis were also excluded 
from the study. No patient was taking any drugs, such as 
oestrogen supplements, thyroxine, glucocorticoid, immu-
nosuppressive, biphosphonate and warfarin. Approval 
for this study was provided by the ethics committees of 
the A. Gemelli University Hospital of Rome and St M. 
Goretti Hospital, Latina (Italy). Informed consent was 
obtained from participating patients.
Histological assays
After a carotid endarterectomy, the specimens were 
briefly rinsed in normal saline solution and then 
immersed in a buffered 10 % formalin fixative and, sub-
sequently, in a decalcifying solution (formic acid). The 
plaques were partly decalcified in order to be sectioned. 
Each specimen was sectioned transversely, perpen-
dicular to the lumen, into 4  mm blocks, starting from 
the specimen base, and then, progressing distally until 
the whole specimen, including the bifurcation, was cut. 
Each block was processed in paraffin, cut into 4 μm sec-
tions, and then, the proximal end of one slice per block 
was stained in sequence with hematoxylin and eosin 
1  % (H&E). The sections were examined for the pres-
ence of atheroma, a necrotic core, hemorrhage, fibrosis, 
calcification and thrombosis. Minimum magnification 
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was used to evaluate the relative necrotic core, whereas, 
maximum magnification was used to evaluate the pres-
ence of hemorrhaging and calcification. The morpho-
logical study focused on the level of the largest plaque 
area, which frequently used to correspond to the level of 
maximal stenosis. The necrotic core was usually located 
in the deeper regions of the plaque and consisted of cho-
lesterol clefts and amorphous material without any viable 
cells or admixed collagen. Calcifications were manifested 
as dark blue, sharply demarcated regions devoid of cells 
in the H&E stains. Intra-plaque hemorrhaging appeared 
as debris containing degenerated red blood cells, as well 
as macrophage engulfment of hemosiderin and giant cell 
development. Carotid plaques were classified as stable 
or unstable according to the American Heart Associa-
tion (AHA) criteria, as defined by Stary and modified by 
Virmani [19, 20].
Biochemical investigation
White blood cell count, serum creatinine, fasting cho-
lesterol, triglycerides and low-density lipoprotein were 
measured. Blood samples were collected from all the 
subjects after an overnight fast. Serum was separated by 
centrifugation of blood samples, stored at −80°C until 
assayed and were treated the same way. Plasma FGF23 
levels were measured using a second-generation C-termi-
nal human enzyme-linked immunosorbent assay (Immu-
topics, San Clemente, CA). The coefficient of variation 
was 9.8 %. HsCRP was determined by using a high-sen-
sitivity ELISA kit (Biocheck Laboratories, Toledo, OH). 
A monoclonal mouse antihuman OPG antibody was 
used as a capture antibody and a biotinylated polyclonal 
goat anti-human OPG antibody was used for detection. 
The intra and inter-assay coefficients of variation were 
3.6 and 10.6  %, respectively. The sensitivity, defined as 
the mean  ±  3 SD of the 0 standard, was calculated to 
be 0.15 pmol/ml. IL-6 levels were assessed by using the 
Quantikine ELISA kit (R&D systems, Minneapolis, MN). 
The serum levels were measured twice in each partici-
pant and the results were averaged.
Statistical analysis
Demographic and clinical data between the groups were 
compared by a Chi squared test and by a t test. FGF23, 
HsCRP, OPG and IL-6 serum levels were compared by 
the Mann–Whitney test. Using a multivariate stepwise 
logistic regression analysis, two models were tested. The 
first one adjusted for conventional risk factors, while in 
the second model, FGF23 and OPG were included for 
testing. All analyses were performed by using the STATA 
version 11.0 for Windows (Statistics/Data Analysis, Stata 
Corporation, College Station, Texas, USA). Statistical sig-
nificance was established at P < 0.05.
Results
The demographic and clinical data of patients are shown 
in Table 1. There were no significant differences between 
the groups in terms of sex (p = 0.561), age (p = 0.204), dia-
betes duration (p =  0.247), smoking current and former 
(p = 0.145 and p = 0.112 respectively), phoshate and cal-
cium levels (p = 0.234 and 0.763 respectively). In contrast, 
the body mass index (BMI), hypertension, coronary artery 
disease (CAD), history of ischemic stroke (HIS), peripheral 
artery disease (PAD), hypercholesterolemia were signifi-
cantly more frequent in patients than controls (Table 1).
Interestingly, FGF23, HsCRP, OPG and IL-6 median 
serum levels, were significantly higher in patients than 
in control subjects (Table  2). In particular the median 
serum FGF23 was 67.7 (59.5–77.8) pg/mL in ICAS and 
43.89 (37.5–50.4) pg/mL in controls (p  <  0.001), the 
median serum HsCRP was 7.95 (6.48-9.55) mg/L in 
ICAS and 3.95 (2.34–5.31) mg/L in controls (p < 0.001), 
the median serum OPG was 4.84 (3.52–5.95) pmol/L in 
ICAS and 2.48 (1.69–3.35) pmol/L in controls (p < 0.001) 
Table 1 Demographic and  clinical data of  study partici-
pants
BMI body mass index, CAD coronary artery disease, HIS history of ischemic 
stroke, PAD peripheral artery disease, LDL-C low-density lipoprotein cholesterol, 
eGFR estimated glomerular filtration rate
* Statistical test performed with Student’s t-test
† Chi square test for categorical values
ICAS WICAS P value
(n = 361) (n = 598)
Men/female, n 125:236 228:370 0.561†
Age (years ± SD) 72.3 ± 4.2 71.9 ± 3.9 0.204*
Diabetes duration, (years ± SD) 13.1 ± 4.2 12.4 ± 3.5 0.247*
BMI (Kg/m2 ± SD) 30.2 ± 6.5 27.6 ± 4.8 <0.01*
Smoking (current), n (%) 125 (34.6) 194 (32.4) 0.145†
Smoking (former), n (%) 163 (45.2) 279 (46.7) 0.112†
Hypertension, n (%) 234 (64.8) 248 (41.5) <0.01†
CAD, n (%) 201 (55.7) 191 (31.9) <0.01†
HIS, n (%) 174 (48.2) 0 (0.0) <0.01†
PAD, n (%) 115 (31.9) 106 (17.7) <0.01†
Hypercholesterolemia, n (%) 291 (80.6) 161 (26.9) <0.01†
LDL-C (mg/dL ± SD) 213 ± 29.8 149 ± 21.2 <0.01†
Triglycerides (mg/dL ± SD) 184 ± 21.3 143 ± 18.8 <0.01†
Statins, n (%) 295 (81.7) 165 (27.6 %) <0.01†
Antihypertensive drugs, n (%) 229 (63.4) 237 (39.6) <0.01†
Anti-diabetic treatment
 Diet only, n (%) 38 (10.5) 65 (10.9) 0.563†
 Oral Agents, n (%) 178 (49.3) 292 (48.8) 0.428†
 Insulin therapy, n (%) 145 (40.2) 241 (40.3) 0.394†
eGFR (mL/min/1.73 m2 ± SD) 68.8 ± 15.2 91.1 ± 19.8 <0.001
Phosphate (mg/dL ± SD) 3.01 ± 1.32 2.89 ± 1.13 0.234
Calcium, mg/dL 9.3 ± 0.4 9.5 ± 0.6 0.763
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and the median serum IL-6 was 62.3 (57.1–68.5) pg/mL 
in diabetic patients with ICAS and 39.1 (33.8–45.2) pg/
mL in diabetic controls (p < 0.001) (Table 2).
Subsequently, we divided the 361 diabetic patients with 
ICAS into unstable (n = 166) (USP) and stable (n = 195) 
plaque (SP) groups. The parameters analyzed in these 
patients are shown in Table 3. Interestingly, hypertension, 
HIS, hypercholesterolemia and low-density lipoprotein 
cholesterol (LDL-C) were significantly more frequent in 
patients with USP than in those with SP (Table 3). Table 4 
analyzed FGF23, HsCRP, OPG and IL-6 median serum 
levels in patients with USP and SP. We found that the 
median levels of the these cytokines were significantly 
higher in USP than in SP subjects [FGF23, 78.4 (68.4–
87.5) vs 34.7 (29.7–41.1) pg/mL, p < 0.001; HsCRP, 9.31 
(7.94–11.1) vs 2.74 (1.92–4.12) mg/L, p  <  0.001; OPG, 
6.04 (4.65–7.34) vs 2.12 (1.02–2.95) pmol/L, p  <  0.001; 
IL–6, 71.5 (66.3–77.4) vs 32.6 (28.8–36.6) pg/mL, 
p < 0.001] (Table 4). 
Finally, a multivariable stepwise logistic regression 
analysis revealed that, in model 1, making adjustments 
for traditional cardiovascular risk factors and established 
inflammatory cytokines, sex, age, smoking, hypertension, 
hypercholesterolemia, triglycerides, LDL-C, HsCRP and 
IL-6 levels were independent determinants of USP in 
T2D patients with ICAS. When FGF23 and OPG were 
included in the multivariable analysis (model 2), FGF23 
and OPG remained independently associated with USP 
in ICAS patients,  and the majority of the conventional 
risk factors in model 1 persisted in being determinants of 
ICAS in model 2 (Table 5).
Discussion
Our present study is the first report to show that high 
serum levels FGF23 are independently associated with 
unstable carotid plaque in the general population with 
T2D. Our findings are consistent with previous reports 
that have found increased levels of FGF23 are an inde-
pendent risk factor for adverse cardiovascular events [9].
In our study we found that the FGF23 median serum 
levels were significantly higher in T2D patients with 
ICAS than in diabetic control [67.7 (59.5–77.8) pg/mL 
and 43.89 (37.5–50.4) pg/mL (p  <  0.001) respectively]. 
In addition, after all 361 diabetic patients with ICAS had 
been divided into unstable and stable plaque, we found 
that the FGF23 median levels of the same cytokines were 
significantly higher in USP than in SP subjects [78.4 
(68.4–87.5) vs 34.7 (29.7–41.1) pg/mL, p < 0.001]. In our 
current study, we confirmed our previous report in which 
OPG serum levels were higher in patients with USP than 
in SP. We found that variant genotypes of the OPG gene 
and high serum OPG as an independent risk factor may 
contribute to the pathogenesis of carotid atherosclerosis. 
The associations between OPG and carotid plaque dem-
onstrated in this study support further investigation into 
the effects of OPG on plaque stability and the possible 
Table 2 Serum levels in  diabetic patients with  and with-
out ICAS
FGF23 fibroblast growth factor-23, HsCRP high-sensitivity C-reactive protein, OPG 
osteoprotegerin, IL-6 interleukin-6
* χ2 test for categorical values
‡ Median (interquartile range)
Variables ICAS WICAS P value
(n = 361) (n = 598)
FGF23, pg/mL (IQR) 67.7 (59.5–77.8)‡ 43.89 (37.5–50.4)‡ <0.001*
HsCRP, mg/L (IQR) 7.95 (6.48–9.55)‡ 3.95 (2.34–5.31)‡ <0.001*
OPG, pmol/L (IQR) 4.84 (3.52–5.95)‡ 2.48 (1.69–3.35)‡ <0.001*
IL-6, pg/mL (IQR) 62.3 (57.1–68.5)‡ 39.1 (33.8–45.2)‡ <0.001*
Table 3 Demographic and  clinical data of  ICAS patients 
with USP and SP
CAD coronary artery disease, HIS history of ischemic stroke, PAD peripheral 
artery disease, LDL-C low-density lipoprotein cholesterol, eGFR estimated 
glomerular filtration rate
* Statistical test performed with Student’s t-test
† Chi square test for categorical values
USP SP P value
(n = 166) (n = 195)
Men/female, n 59:107 71:124 0.372†
Age (years ± SD) 72.1 ± 3.9 72.3 ± 4.1 0.315*
Smoking (current), n (%) 58 (34.9) 67 (34.4) 0.274†
Smoking (former), n (%) 74 (44,6) 89 (45.6) 0.112†
Hypertension, n (%) 119 (71.7) 115 (60.0) 0.004†
CAD, n (%) 92 (55.4) 109 (55.9) 0.159†
HIS, n (%) 102 (61.4) 72 (36.9) 0.001†
PAD, n (%) 53 (31.9) 62 (31.8) 0.195†
Hypercholesterolemia, n (%) 141 (85.0) 150 (76.9) 0.003†
LDL-C (mg/dL ± SD) 220 ± 31.4 206 ± 27.4 0.03†
eGFR (mL/min/1.73 m2 ± SD) 67.3 ± 13.1 69.1 ± 12.7 0.593
Table 4 Serum levels in  diabetic patients with  unstable 
and stable plaques
FGF23 fibroblast growth factor-23, HsCRP high-sensitivity C-reactive protein, OPG 
osteoprotegerin, IL-6 interleukin-6
* χ2  test for categorical values
‡ Median (interquartile range)
USP SP
(n = 166) (n = 195)
FGF23, pg/mL (IQR) 78.4 (68.4–87.5)‡ 34.7 (29.7–41.1)‡ <0.001*
HsCRP, mg/L (IQR) 9.31 (7.94–11.1)‡ 2.74 (1.92–4.12)‡ <0.001*
OPG, pmol/L (IQR) 6.04 (4.65–7.34)‡ 2.12 (1.02–2.95)‡ <0.001*
IL-6, pg/mL (IQR) 71.5 (66.3–77.4)‡ 32.6 (28.8–36.6)‡ <0.001*
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role of OPG as a biomarker to identify patients with, or at 
risk of, cerebrovascular events [21].
In the final step, a multivariable stepwise logistic regres-
sion analysis revealed FGF23 and OPG remained inde-
pendently associated with USP in ICAS diabetic patients 
(model 2) and the majority of the conventional risk fac-
tors in model 1 persisted in being determinants of ICAS 
in model 2.
In the pathogenesis of atherosclerosis, the potential 
role of FGF23 may be partially explained through its 
involvement in the complex process of vascular calci-
fication. In the atherosclerotic process, vascular cal-
cification plays an important role and the rupture of 
unstable plaques leads to critical atherosclerotic stenosis 
and acute cerebrovascular or cardiovascular syndrome 
[22]. Several studies showed that higher FGF23 levels 
were associated with the development of artery calcifica-
tion, particularly in the presence of chronic kidney dis-
ease [23, 24]. Recently Masai et  al. found serum FGF23 
levels were also associated with coronary calcification 
independent of classical cardiovascular risk factors in 
patients with suspected CAD and with preserved renal 
function [9], while Xiao et  al. reported an independent 
association between circulating FGF23 concentration 
and the severity and extent of coronary artery stenosis in 
the coronary angiographic patients [25]. Thus, it is rea-
sonable to think FGF23 could play an important role in 
the vascular calcification process, since vascular calcifi-
cation is associated with atherosclerosis, which may help 
explain the association between elevated FGF23 and the 
severity of atherosclerotic stenosis. The rupture of unsta-
ble plaques leads to coronary stenosis and acute coronary 
syndrome. Although calcified plaque has been consid-
ered as the established, stable and quiescent atheroma 
[26], recent studies reported that spotty distribution of 
calcium in calcified plaque was an important characteris-
tic of vulnerable plaque leading to plaque rupture, which 
was more frequently observed in the culprit lesions of 
patients with acute coronary syndrome [27, 28]. Previ-
ously, a positive association between recurrent cardio-
vascular disease and high FGF23 levels was reported in 
The Heart Soul Study [12]. FGF23 was also positively 
associated with risk of incident heart failure (HF) and 
total cardiovascular events in the Cardiovascular Health 
Study [29] and with cardiovascular mortality in the 
Uppsala Longitudinal Study of Adult Men [30]. Aoki 
et al., however, reported that vascular calcification is not 
linked to other bone-related humoral factors including, 
FGF23, while serum FGF23 was elevated only in subjects 
with stage 4 nephropathy [31]. In another study, plasma 
cFGF23 levels did not significantly differ between dia-
betic patients and non-diabetic subjects [32].
Previous clinical studies have shown elevated OPG lev-
els in patients with atherosclerosis and increased OPG 
levels with the severity of cardiovascular disease such 
as peripheral artery disease [33] and heart failure [34], 
with symptomatic carotid stenosis [35], unstable angina 
[36] and vulnerable carotid plaques [37]. The high con-
centrations of OPG could be responsible for a number 
of changes within the atherosclerotic plaque that would 
promote plaque instability. Within bone, OPG has been 
shown to modulate the release of matrix-degrading 
enzymes, such as cathepsins and therefore, it may also 
have an important influence on plaque stability [38].
In our population, we found that FGF23 serum levels 
were significantly increased and associated with USP 
independent of serum phosphorus level, which still 
remained within the normal range in the majority of the 
patients. Indeed, the increase in FGF23 concentration 
could be a compensatory mechanism to maintain serum 
phosphorus level in the normal range [39].
Our study has some potential limitations. It was a 
case–control study. Therefore, a recruitment and survival 
bias cannot be excluded. Our data were obtained from a 
cohort of European descent and includes subjects with 
other cardiovascular diseases. Thus, comorbidity might 
Table 5 Multivariable stepwise logistic regression model 
for presence of USP
Variable OR (95 % CI) P value
Model 1
 Sex 1.03 (0.98–1.10) 0.110
 Age 1.19 (1.13–1.29) 0.229
 Smoking (current) 26.33 (4.24–181.32) 0.001
 Smoking (former) 1.15 (1.06–1.23) 0.142
 Hypertension 19.23 (4.879–86.12) <0.001
 Hypercholesterolemia 6.45 (1.57–26.97) 0.019
 Triglycerides 0.45 (0.11–1.03) 0.035
 LDL-C 9.45 (1.39–86.25) 0.039
 HsCRP 35.03 (8.16–139.03) <0.001
 IL-6 5.51 (2.05–16.39) 0.002
Model 2
 Sex 0.85 (0.20–0.96) 0.083
 Age 1.39 (1.07–1.55) 0.169
 Smoking (current) 65.8 (3.91–880.7) 0.002
 Smoking (former) 1.22 (1.11–1.28) 0.175
 Hypertension 32.05 (5.11–195.56) <0.001
 Hypercholesterolemia 8.97 (1.14–48.37) 0.016
 Triglycerides 0.85 (0.34–1.44) 0.004
 LDL-C 18.24 (2.31–183.58) 0.017
 HsCRP 73.79 (9.69–556.45) <0.001
 IL-6 8.69 (2.89–19.79) <0.001
 OPG 3.93 (1.81–5.37) 0.039
 FGF23 5.89 (2.15–15.45) 0.009
Page 6 of 7Biscetti et al. Cardiovasc Diabetol  (2015) 14:139 
represent a confounding factor and the generalization of 
our findings to other age groups or ethnicities is unclear. 
The size of the population studied is relatively small and 
could lead to false positive results. Our findings need to 
be confirmed in larger samples and should also be tested 
in groups of different ethnic origins. We cannot rule out 
the possibility of residual confounding by other factors 
such as bone status, 1,25(OH)2D or PTH levels. Finally, 
prescribed or self-administered calcium and vitamin D 
supplements and dietary phosphate intake have not been 
considered in our calculations.
In conclusion, the present study identifies FGF23 
serum levels as an independent risk factor for unsta-
ble carotid plaque in the general population with type 
2 diabetes. The association was independent of tradi-
tional cardiovascular risk factors and kidney function. 
The data further suggest a role for FGF23 as a reliable 
biomarker in atherosclerotic disease. Future studies 
are needed to investigate the potential biological role 
of FGF23 in the pathogenesis of atherosclerotic disease 
and to evaluate whether FGF23 is a modifiable cardio-
vascular risk factor.
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